Human Anti-CD274 Recombinant Antibody (clone MEDI4736) (CAT#: HPAB-0528-FY)

Figure 1 MEDI4736 binds specifically to PD-L1, inhibits its interactions with PD-1 and CD80, and does not trigger ADCC.

A, the signal derived in an ELISA from MEDI4736 binding to human PD-L1 or the related proteins B7-H3 and B7-DC. B, the % specific binding observed between PD-1 and PD-L1 in an HTRF-based ligand inhibition assay in the presence of increasing concentrations of MEDI4736 or an isotype control antibody. C, the % specific binding observed between CD80 and PD-L1 in an HTRF-based ligand inhibition assay in the presence of increasing concentrations of MEDI4736 or an isotype control antibody. D, the level of NFAT-driven luciferase activity in a CD16a-transfected NK cell line following incubation with SKBR3 cells coated in MEDI4736 or a version of MEDI4736 bearing a wild-type IgG1 Fc domain.

Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., ... & Bannister, D. (2015). Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer immunology research, 3(9), 1052-1062.

Figure 2 MEDI4736 overcomes PD-L1–mediated inhibition of T-cell activation.

The effect of increasing concentrations of MEDI4736 on (A) thymidine incorporation and (B) IFNγ release in primary T cells stimulated with beads coated in anti-CD3, anti-CD28, and either PD-L1 or irrelevant isotype control IgG. C, thymidine incorporation in a MLR in the presence of increasing concentrations of MEDI4736 or an isotype control antibody.

Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., ... & Bannister, D. (2015). Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer immunology research, 3(9), 1052-1062.

Figure 3 MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

A, fluorescence observed on HPAC and A375 cell lines by flow cytometry following staining with an anti–PD-L1 (filled) antibody or an isotype control antibody (dotted). B, HPAC tumor volumes (mm3) in NOD/SCID mice following coimplantation of primary human T cells and administration of MEDI4736 i.p. at 5, 1, 0.1, and 0.01 mg/kg twice per week for 3 weeks as indicated. C, A375 tumor volumes (mm3) in NOD/SCID mice following coimplantation of primary human T cells and administration of MEDI4736 i.p. at 5, 1, and 0.1 mg/kg twice per week for 3 weeks as indicated. D, A375 tumor volumes (mm3) in NOD/SCID mice without coimplantation of primary human T cells and administration of MEDI4736 i.p. at 1 and 0.1 mg/kg twice per week for 3 weeks as indicated.

Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., ... & Bannister, D. (2015). Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer immunology research, 3(9), 1052-1062.